1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Kythera's lead candidate appears to reduce chin fat in Phase II

 
• By Katie McQue

Kythera Biopharmaceuticals' lead product candidate, ATX-101, appeared to have been successful in reducing submental (under-the-chin) fat in two Phase II trials.

Kythera Biopharmaceuticals' lead product candidate, ATX-101, appeared to have been successful in reducing submental (under-the-chin) fat in two Phase II trials.

According to the Los Angeles-based company, ATX-101 is a first-in-class injectable product for the removal of localised facial fat deposits.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Prilenia, Ferrer Map Out Plans For Pridopidine In Huntington’s

 
• By Alaric DeArment

The companies announced the publication of Phase III data that they said provide rationale for moving forward in a confirmatory trial.

AC Immune Cuts Workforce As Key Parkinson’s Readout Nears

 
• By Andrew McConaghie

The Swiss neuroscience specialist has extended its cash runway into late 2027, but will still need positive readouts in the coming months, including for its wholly owned Parkinson’s candidate.

‘Attenuated’ Survival Benefit In Bemarituzumab Trial Delays Filing Plans

 
• By Alaric DeArment

Amgen and Zai Lab said the final analysis of the FORTITUDE-101 trial showed a decreased magnitude of OS benefit in first-line gastric cancer.

AL-S Pharma’s AP-101 Shows Efficacy In ALS Clinical Trial

 
• By Jessica Merrill

The Phase II study tested AP-101 safety and tolerability as the primary endpoint but showed “clinically meaningful” efficacy in exploratory endpoints.

More from R&D

Xoma On Its Royalty Model And Cleaning Up ‘Zombie’ Companies

 
• By Manas Mishra and Andrew McConaghie

Seizing an opportunity to buy out struggling 'zombie' biotechs, Xoma is helping to return investor cash and pick up potential bargain assets for itself. Its CEO and chief investment officer explained their approach to Scrip.

Sanofi Shares Slide Despite Amlitelimab Eczema Win

 
• By Kevin Grogan

The OX40 ligand-targeting drug’s efficacy is seen as light compared with existing therapies.

Zydus Beats Gilead, Ipsen On Cholangitis Primary Endpoint But Pruritus Data Is Key

 
• By Vibha Ravi

Zydus's saroglitazar beat both Gilead’s Livdelzi and Ipsen’s Iqirvo on biochemical response in topline results from a Phase IIb/III trial in primary biliary cholangitis, but subtle differences in definitions, data on pruritus or itching and other factors could be key to approval and adoption.